|
BBIO | Bridgebio Pharma, Inc. |
|
|
BBIO | Bridgebio Pharma, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.17 |
| Leverage | 292.61% |
| Market Cap | $ 11.4B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -802.6m |
| Margin | -208.39% |
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.